Evaluation of L6, an anti-carcinoma murine monoclonal antibody, in tumor-bearing nude mice

Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue

“…Localization studies performed in nude mice showed (a) a great similarity between mAb L6 and the L6 poly(Lys)-AcoDM conjugate with respect to uptake in tumor, and (b) that the kinetics of mAb and conjugate were also similar. The clearance and tumor uptake data agreed well with previous reports [20,26]. Both materials accumulated in tumor to a larger extent than the control mAb 1F5.…”

Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity

“…The current interest in mAbbased serotherapies for the treatment of malignant disease is based on their potential to discriminate neoplastic cell populations from normal tissues. Major therapeutic apOffprint requests to: G. R. Braslawsky proaches using mAbs are (a) the use of unconjugated mAb to activate or enhance endogenous defense mechanisms following antigen binding [13,18], and (b) their use as carriers of radioisotopes [17, 21], toxins [19,[22][23][24], or chemotherapeutic drugs [7,9,11,12, 32].mAbs that bind to cell-surface receptors can enter the cell by a process similar to receptor-mediated endocytosis [10, 25, 26]. mAbs can also be internalized during membrane utilization or membrane biosynthesis [27].…”

Cloning and expression of the tumor-associated antigen L6.

“…The murine mAb L6 recognizes a cell surface antigen highly expressed on lung, breast, colon, and ovarian carcinomas (4), and it is able to mediate antibody-dependent cellular cytotoxicity with human mononuclear cells and complement-dependent cytotoxicity with human complement as well as to localize to antigen-positive human tumor cells in nude mice (5) and inhibit their outgrowth (6). Though the L6-defined antigen is also present on some normal cells, endothelial cells in particular (ref.…”